CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that additional holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $40.2 million in aggregate principal amount of those notes for approximately 1.9 million shares of the Company’s common stock, which is approximately 112,000 shares more than the number of shares into which the notes were convertible under their original terms. The additional shares largely relate to unpaid interest through February 2010, when the notes would have been callable by the Company. Added to the agreements to exchange $103.3 million in aggregate principal amount announced earlier today, this brings the total amount of notes to be exchanged to $143.5 million.
